Afnan Mohammed H. Almutairi

Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review

Abdulrahman Arshed N. Alharfy, Marwan Saleh D. Albalawi, Abdulmajeed Mousa Alzahrani, Ruby Naif M. Alsubaie, Amani Ahmad S. Albalawi, Waad Ali Alkaabneh, Abdullah Ibrahim Altidlawi, Amal Nafea J. Alharbi, Afnan Mohammed H. Almutairi & Rola Ali S. Alotabi · Journal of Pharmaceutical Research International · 2021

Neovascular glaucoma (NVG) is an aggressive type of glaucoma, which often results in poor visual outcomes. Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia. Bevacizumab is a humanized...

Open access Research Article 10.9734/jpri/2021/v33i40A32237

Overview of the Presentation and Updated Management of Sinusitis

Khaled Abdullah S. Alasmari, Lena Defallah G. Alzahrani, Sultan Suliman Q. Al-Ruwaili, Rahaf Naif A. Alenezi, Sarah Fahad M. Bukhari, Sarah Muqbil B. Altmimi, Shaden Akram A. Alanazi, Lama Muaysh M. Aljohani, Alshaymaa Akram A. Alanazi & Afnan Mohammed H. Almutairi · Journal of Pharmaceutical Research International · 2021

Acute and chronic sinusitis are common primary care presentations. They are caused by mucosal inflammation, which inhibits mucociliary function of the nose and paranasal sinuses. Because it affects the mucous membranes that line both the nose and the sinuses, the complete medical...

Open access Research Article 10.9734/jpri/2021/v33i39A32136